Pfizer Loses U.K. Patent Appeal Over $4.8 Billion Lyrica Drug

摘要

Pfizer Inc. lost an appeal in a U.K. patent dispute over Lyrica, one of the company's top-selling drugs (Warner-Lambert Company LLC v. Genetics (UK) Ltd., EWCA, No. A3/2015/3602, 10/13/16). Three London judges Oct. 13 upheld a 2015 ruling that Allergan Pic's Actavis unit didn't infringe Pfizer patents with its version of the drug pregabalin. The disputed patent covers the use of pregabalin for the treatment of pain. Teva bought the business this year.